Results 31 to 40 of about 7,686 (201)

PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease. [PDF]

, 2017
BACKGROUND: Despite the availability of effective drug therapies that reduce low-density lipoprotein (LDL)-cholesterol (LDL-C), cardiovascular disease (CVD) remains an important cause of mortality and morbidity.
Casas, Juan P, Hingorani, Aroon D, Overington, John P, Pearce, Lucy S, Schmidt, Amand F, Wilkins, John T   +5 more
core   +2 more sources

Evolocumab is Initiated in Central and Eastern Europe at Much Higher LDL-C Levels Than Recommended in Guidelines: Results from the Observational HEYMANS Study

Journal of Cardiovascular Pharmacology and Therapeutics, 2023
Purpose: We examined clinical characteristics and low-density lipoprotein cholesterol (LDL-C) lowering in patients initiating evolocumab in real-world practice in a Central and Eastern European (CEE) cohort from the pan-European HEYMANS study.
Vladimír Blaha MUDr, CSc, Roman Margoczy MUDr, Ivo Petrov MD, Arman Postadzhiyan MD, PhD, FESC, FACC, Katarína Rašlová MUDr, CSc, Hana Rosolová MUDr, DrSc, Ian Bridges MSc, Nafeesa N. Dhalwani PhD, Marie Zachlederova PhD, Kausik K. Ray FESC   +9 more
doaj   +1 more source

The 1(st) and the 2(nd) Italian Consensus Conferences on low-density lipoprotein-apheresis. A practical synopsis and update [PDF]

, 2016
The clinical indications and guidelines for low-density lipoprotein (LDL)-apheresis set by the 1(st) Italian Consensus Conference held in Ostuni in 1990 and completed in 1992, but never published, are reported schematically.
Stefanutti, Claudia
core   +1 more source

Real-World Insights Into Evolocumab Use in Patients With Hyperlipidemia: Canadian Analysis From the ZERBINI Study

CJC Open, 2022
Background: The 2021 Canadian Cardiovascular Society guidelines recommend proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitor therapy in patients with atherosclerotic cardiovascular disease whose low-density lipoprotein cholesterol (LDL-C ...
Milan Gupta, MD, G.B. John Mancini, MD, Rajvi J. Wani, PhD, Vineeta Ahooja, MD, Jean Bergeron, MD, MSc, Priya Manjoo, MD, A. Shekhar Pandey, MD, Maureen Reiner, MS, MA, Johnny Beltran, MD, MSc, Thiago Oliveira, MD, Erin S. Mackinnon, PhD   +10 more
doaj   +1 more source

Intrinsic Motivation [PDF]

, 2014
Employs a literature review to describe intrinsic motivation as the force behind pro-social behavior, or when individuals willingly engage in behavior that is costly to them but benefits others.
Brock, J. Michelle, Leonard, Kenneth L., Serneels, Pieter   +2 more
core   +1 more source

Effects of Evolocumab Added to Moderate-Intensity Statin Therapy in Chinese Patients With Acute Coronary Syndrome: The EMSIACS Trial Study Protocol

Frontiers in Physiology, 2021
Background: Several studies have demonstrated that using a higher dose of statin can easily induce liver injury and myopathy. Low-density lipoprotein cholesterol (LDL-C) is a well-established modifiable risk factor for cardiovascular disease; however ...
Jing Gao, Jing Gao, Jing-Yu Liu, Peng-Ju Lu, Jian-Yong Xiao, Ming-Dong Gao, Chang-Ping Li, Zhuang Cui, Yin Liu, Yin Liu   +9 more
doaj   +1 more source

Circulating Levels of Proprotein Convertase Subtilisin/Kexin Type 9 and Arterial Stiffness in a Large Population Sample: Data From the Brisighella Heart Study [PDF]

, 2017
Proprotein convertase subtilisin/kexin type 9 (PCSK9) circulating levels are significantly associated with an increased risk of cardiovascular events.
Borghi, Claudio, Botta, Margherita, Cicero, Arrigo F. G., D'Addato, Sergio, Ferri, Nicola, Fogacci, Federica, Giovannini, Marina, Magni, Paolo, Marchiano, Silvia, Rosticci, Martina, Ruscica, Massimiliano   +10 more
core   +2 more sources

Effect of PCSK9 Inhibitor on Contrast-Induced Acute Kidney Injury in Patients with Acute Myocardial Infarction Undergoing Intervention Therapy

Cardiology Research and Practice, 2022
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have been shown to inhibit pyroptosis and apoptosis, which play important roles in the development and progression of contrast-induced acute kidney injury (CI-AKI).
Yu Ma, Lei Zha, Qi Zhang, Lu Cao, Ru Zhao, Jing Ma, Kai Hou, Yue Pan, Hongliang Cong, Ximing Li   +9 more
doaj   +1 more source

Natriuretic Peptides in the Cardiovascular System. Multifaceted Roles in Physiology, Pathology and Therapeutics [PDF]

, 2019
The natriuretic peptides (NPs) family includes a class of hormones and their receptors needed for the physiological control of cardiovascular functions. The discovery of NPs provided a fundamental contribution into our understanding of the physiological ...
Rubattu, Speranza, Volpe, Massimo
core   +1 more source

Real-World Insights into Evolocumab Use in Patients with Hyperlipidemia Across Five Countries: Analysis from the ZERBINI Study

Cardiology and Therapy, 2023
Introduction This study characterizes patients receiving evolocumab in clinical practice and assesses treatment effectiveness, safety and persistence outcomes across five countries.
Milan Gupta, Rajvi J. Wani, Khalid Al Faraidy, Jean Bergeron, Eduardo Contreras, Angel Alberto Garcia Peña, G. B. John Mancini, Francisco Padilla, Abel Alberto Pavia Lopez, Kiran Philip, Johnny Wu, Erin S. Mackinnon   +11 more
doaj   +1 more source